BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance
Diana Eccles(Princess Anne Hospital), David E. Goldgar(University of Utah), Ronald H. Driessen, Noralane M. Lindor(Mayo Clinic in Arizona), Marinus J. Blok(Maastricht University), Tuya Pal(Vanderbilt University Medical Center), Michael T. Parsons, Christi J. van Asperen(Loyola University Medical Center), Miguel de la Hoya, Álvaro N.A. Monteiro(Moffitt Cancer Center), Orland Dı́ez(Vall d'Hebron Hospital Universitari), Katherine L. Nathanson(Translational Therapeutics (United States)), Dominique Stoppa‐Lyonnet(Centre National de la Recherche Scientifique), Pål Møller(Unknown), Rita K. Schmutzler(Weatherford College), Amanda B. Spurdle(QIMR Berghofer Medical Research Institute), K. Rheim, Gillian Mitchell(Peter MacCallum Cancer Centre), Fergus J. Couch(Mayo Clinic), S. M. Domchek(QIMR Berghofer Medical Research Institute), E. Gómez(Maastricht University Medical Centre)
Cited by 220
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k